TABLE 1.

Thirty-nine predicted potential drugs and their targeted DEGs in cervical cancer.

DrugBank ID	Drug	p-value	Gene
DB00075	Muromonab	< 0.001	CD247, CD3D, CD3E, CD3G, FCGR1A, FCGR2B
DB00098	Antithymocyte immunoglobulin	< 0.001	CD4, CD86, FCGR2B, ITGAL
DB06681	Belatacept	< 0.001	CD80, CD86
DB01281	Abatacept	< 0.001	CD80, CD86
DB00095	Efalizumab	0.001	FCGR1A, FCGR2B, ITGAL
DB00004	Denileukin diftitox	0.001	IL2RA, IL2RG
DB12698	Ibalizumab	0.001	CCR5, CD4
DB00111	Daclizumab	0.001	FCGR1A, FCGR2B, IL2RA
DB00074	Basiliximab	0.002	FCGR1A, FCGR2B, IL2RA
DB02010	Staurosporine	0.002	ITK, LCK, ZAP70
DB00005	Etanercept	0.003	FCGR1A, FCGR2B, TNFRSF1B
DB06607	Catumaxomab	0.005	CD3E, FCGR1A
DB00041	Aldesleukin	0.010	IL2RA, IL2RG
DB11767	Sarilumab	0.015	FCGR1A, FCGR2B
DB00112	Bevacizumab	0.019	FCGR1A, FCGR2B
DB00081	Tositumomab	0.019	FCGR1A, FCGR2B
DB00110	Palivizumab	0.019	FCGR1A, FCGR2B
DB00028	Immune Globulin Human	0.019	FCGR1A, FCGR2B
DB00087	Alemtuzumab	0.019	FCGR1A, FCGR2B
DB00092	Alefacept	0.019	FCGR1A, FCGR2B
DB00002	Cetuximab	0.022	FCGR1A, FCGR2B
DB00073	Rituximab	0.022	FCGR1A, FCGR2B
DB00078	Ibritumomab tiuxetan	0.022	FCGR1A, FCGR2B
DB00108	Natalizumab	0.022	FCGR1A, FCGR2B
DB00056	Gemtuzumab ozogamicin	0.022	FCGR1A, FCGR2B
DB00051	Adalimumab	0.022	FCGR1A, FCGR2B
DB00072	Trastuzumab	0.030	FCGR1A, FCGR2B
DB00054	Abciximab	0.030	FCGR1A, FCGR2B
DB01254	Dasatinib	0.022	BTK, FGR, LCK
DB00071	Insulin Pork	0.034	HLA-DQA2
DB00707	Porfimer sodium	0.039	HLA-DQB1
DB11714	Durvalumab	0.039	CD80
DB11626	Tasonermin	0.039	TNFRSF1B
DB05943	Resatorvid	0.039	IL2RG
DB04835	Maraviroc	0.039	CCR5
DB09052	Blinatumomab	0.039	CD3D
DB00895	Benzylpenicilloyl Polylysine	0.039	FCER1G
DB05501	AMD-070	0.039	CCR5
DB01809	Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D] Pyrimidin-4-Ylamine	0.039	HCK